One promising immunotherapy is recombinant interleukin-2 (IL2) which expands antigen-specific CD8 T cell populations (20), and it has been shown to induce durable disease control in some patients with metastatic melanoma and renal cell carcinoma (21–23). The gene discussed is IL2; the disease is renal cell carcinoma.